Anti-Diabetes Drugs - Indonesia

Indonesia

In Indonesia, the revenue in the Anti-Diabetes Drugs market is forecasted to reach US$0.42bn by 2024.
Looking ahead, the market is expected to exhibit a compound annual growth rate (CAGR) of 7.75% from 2024 to 2029, resulting in a market volume of US$0.61bn by 2029.
It is worth noting that, compared to other countries, United States is projected to generate the highest revenue in the Anti-Diabetes Drugs market, with an estimated value of US$37,840.00m in 2024.
In recent years, Indonesia has seen an increasing demand for locally-produced anti-diabetes drugs, as the government focuses on promoting domestic pharmaceutical industry.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Indonesia has been experiencing steady growth in recent years.

Customer preferences: As the population of Indonesia continues to age and become more urbanized, the number of people with diabetes is increasing. This has led to a growing demand for anti-diabetes drugs in the country. Additionally, there has been a shift in consumer preferences towards more convenient and effective treatment options.

Trends in the market: One of the key trends in the Anti-Diabetes Drugs market in Indonesia is the increasing popularity of combination therapies. These drugs combine multiple active ingredients to provide a more comprehensive treatment approach. Another trend is the growing adoption of injectable drugs, which offer more precise dosing and better blood sugar control.

Local special circumstances: Indonesia has a large population and a growing middle class, which is driving demand for healthcare services. However, the country also faces challenges in terms of healthcare infrastructure and access to care, particularly in rural areas. This has led to a focus on improving healthcare delivery and expanding access to treatment for chronic diseases like diabetes.

Underlying macroeconomic factors: The Indonesian economy has been growing steadily in recent years, which has helped to support the growth of the Anti-Diabetes Drugs market. However, the country also faces challenges such as inflation and currency fluctuations, which can impact the affordability of healthcare services and drugs. Additionally, the government has been implementing healthcare reforms aimed at improving access to care and reducing costs, which could have an impact on the Anti-Diabetes Drugs market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.